Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia

BACKGROUND: The aim of this study was to assess whether minimal residual disease (MRD) at the end of induction front-line treatment can serve as a surrogate endpoint for event-free survival (EFS) in childhood B-lineage acute lymphoblastic leukemia. METHODS: The analysis was based on individual data...

Descripción completa

Detalles Bibliográficos
Autores principales: Galimberti, Stefania, Devidas, Meenakshi, Lucenti, Ausiliatrice, Cazzaniga, Giovanni, Möricke, Anja, Bartram, Claus R, Mann, Georg, Carroll, William, Winick, Naomi, Borowitz, Michael, Wood, Brent, Basso, Giuseppe, Conter, Valentino, Zimmermann, Martin, Suciu, Stefan, Biondi, Andrea, Schrappe, Martin, Hunger, Stephen P, Valsecchi, Maria Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649800/
https://www.ncbi.nlm.nih.gov/pubmed/31360884
http://dx.doi.org/10.1093/jncics/pky069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649800/
https://www.ncbi.nlm.nih.gov/pubmed/31360884
http://dx.doi.org/10.1093/jncics/pky069

Ejemplares similares